PCSK9 and fibrosis: In a mouse model of fibrosis, PCSK9 deletion alleviated hepatic inflammation, accompanied with a reduction in the plasma levels of lipopolysaccharide (LPS), aspartate aminotransferase (AST), and alanine aminotransferase (ALT), which are representative biomarkers of liver injury (Zou et al., 2020).